Market Size and Overview
The RNA targeted therapeutics market is estimated to be valued at USD 1.81 Bn in 2025 and is expected to reach USD 15.10 Bn by 2032, growing at a compound annual growth rate (CAGR) of 35.4% from 2025 to 2032.
Emerging RNA interference and antisense oligonucleotide pipelines for oncology, rare genetic disorders and metabolic diseases are driving expansion across key market segments and refining the market scope. Our comprehensive RNA Targeted Therapeutics Market report highlights critical market drivers like precision payload design and addresses market restraints and challenges such as delivery barriers and regulatory scrutiny. Rapid advances in nanoparticle delivery and mRNA stabilization have spurred robust market revenue growth, demonstrating significant industry size expansion and bolstering business growth.
Investment Scenario
Investment scenario in the RNA Targeted Therapeutics Market shows strong capital influx in 2025, with VC firms and biopharma alliances driving RNA Targeted Therapeutics Market revenue and supporting business growth. Major funding rounds include:
• Q1 2025: Ionis Pharmaceuticals secured USD 150 Mn Series C for antisense platform expansion, marking a 20% increase in R&D budget.
• Q2 2025: Arrakis Therapeutics raised USD 200 Mn from private equity to scale RNAi manufacturing capacity.
• Q3 2025: Partnership between Moderna and a specialty CDMO attracted USD 120 Mn equity infusion to accelerate mRNA stabilization projects.
M&A activity intensified with Alnylam acquiring a nanoparticle delivery startup for USD 180 Mn. These investment trends reflect broader market trends and investor sentiment, informing future market growth strategies and setting a benchmark for market analysis.
Regional Opportunities
Asia Pacific is projected to capture increasing RNA Targeted Therapeutics Market share, driven by government grants in China and South Korea allocating USD 500 Mn toward R&D infrastructure in 2024. Favorable export incentives under Japan’s new biotechnology policy have boosted RNAi shipment volumes by 18% Y-o-Y through Q2 2025. North America continues to dominate market opportunities with the U.S. FDA’s fast-track approvals reducing time-to-market by 30%, while Canada’s new tax credits for biomanufacturing are catalyzing production hubs. Europe’s evolving regulatory framework in the EU Health Union initiative has encouraged supplier entries, with three new CDMO facilities launching in Germany and Ireland by late 2025. These regional dynamics align with the market forecast for uneven but robust growth across geographies.
Key Players
Major market companies and players driving RNA Targeted Therapeutics Market trends include:
• Abivax: Established regional production hub in Switzerland (2024), boosting European supply by 25%.
• AC Immune: Partnered with a Japanese CDMO in 2025, expanding Asia Pacific market reach and increasing market share in neurodegenerative segments.
• Arrakis Therapeutics: Opened a U.S. RNAi manufacturing facility (2025), accelerating pipeline delivery and reducing costs by 15%.
• eFFECTOR Therapeutics: Secured USD 100 Mn in Series B funding (2024) for small-molecule conjugates, enhancing market revenue.
• Eloxx Pharmaceuticals: Entered a licensing agreement in Latin America (2025), adding three new therapeutic candidates.
• Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Moderna, BioNTech, Sarepta Therapeutics and Silence Therapeutics: Each expanded global footprint through collaborations or new market entry, collectively increasing industry share and supporting market growth strategies.
FAQs
Who are the dominant players in the RNA Targeted Therapeutics Market?
Leading innovators include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Abivax, AC Immune and Arrakis Therapeutics, alongside mRNA pioneers such as Moderna and BioNTech.
2. What will be the size of the RNA Targeted Therapeutics Market in the coming years?
Projections indicate growth from USD 1.81 Bn in 2025 to approximately USD 15.10 Bn by 2032, driven by expanding therapeutic pipelines and delivery technology advances.
3. Which end-user industries have the largest growth opportunity?
Biopharmaceutical firms targeting rare genetic disorders and oncology indications hold the greatest potential due to high unmet clinical needs and favorable reimbursement prospects.
4. How will market development trends evolve over the next five years?
Key trends include enhanced nanoparticle delivery platforms, lipid nanoparticle (LNP) stabilization and CRISPR-based modalities, shaping R&D priorities and pipeline strategies.
5. What is the nature of the competitive landscape and challenges in the RNA Targeted Therapeutics Market?
Competition spans agile biotech start-ups and global pharma, with market challenges centered on delivery efficiency, safety profiles and evolving regulatory requirements.
6. What go-to-market strategies are commonly adopted in the RNA Targeted Therapeutics Market?
Strategic alliances with CDMOs, co-development partnerships and regional licensing agreements are widely used to accelerate development timelines and optimize cost structures.
‣ Get More Insights On: RNA Targeted Therapeutics Market
‣ Get this Report in Japanese Language: RNA標的治療薬市場
‣ Get this Report in Korean Language: RNA표적치료제시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)